IRIS
FUMAROLA, Claudia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.312
AS - Asia 4.066
EU - Europa 3.453
SA - Sud America 543
AF - Africa 218
Continente sconosciuto - Info sul continente non disponibili 185
OC - Oceania 10
Totale 13.787
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.205
SG - Singapore 1.364
CN - Cina 1.101
IT - Italia 1.068
VN - Vietnam 640
IE - Irlanda 434
BR - Brasile 419
FI - Finlandia 417
SE - Svezia 393
DE - Germania 300
HK - Hong Kong 289
BD - Bangladesh 188
FR - Francia 161
UA - Ucraina 136
ZA - Sudafrica 131
NL - Olanda 119
IN - India 108
GB - Regno Unito 107
TR - Turchia 87
RU - Federazione Russa 79
CA - Canada 62
AT - Austria 54
AR - Argentina 49
BE - Belgio 49
CI - Costa d'Avorio 41
PL - Polonia 33
KR - Corea 32
IQ - Iraq 31
JP - Giappone 29
ID - Indonesia 27
ES - Italia 25
MX - Messico 23
CZ - Repubblica Ceca 21
EC - Ecuador 21
PK - Pakistan 21
CO - Colombia 20
PH - Filippine 19
TH - Thailandia 17
PS - Palestinian Territory 12
VE - Venezuela 11
JO - Giordania 10
LT - Lituania 10
MA - Marocco 10
SA - Arabia Saudita 10
EG - Egitto 9
IR - Iran 9
UZ - Uzbekistan 8
KE - Kenya 7
AU - Australia 6
CL - Cile 6
HU - Ungheria 6
LB - Libano 6
LU - Lussemburgo 6
MY - Malesia 6
AE - Emirati Arabi Uniti 5
AL - Albania 5
KG - Kirghizistan 5
NP - Nepal 5
PY - Paraguay 5
SY - Repubblica araba siriana 5
BO - Bolivia 4
CH - Svizzera 4
JM - Giamaica 4
MD - Moldavia 4
NZ - Nuova Zelanda 4
OM - Oman 4
PE - Perù 4
PT - Portogallo 4
QA - Qatar 4
RO - Romania 4
TN - Tunisia 4
TW - Taiwan 4
UY - Uruguay 4
AZ - Azerbaigian 3
DZ - Algeria 3
IL - Israele 3
PA - Panama 3
AO - Angola 2
CR - Costa Rica 2
CY - Cipro 2
DO - Repubblica Dominicana 2
EE - Estonia 2
ET - Etiopia 2
GA - Gabon 2
GE - Georgia 2
GT - Guatemala 2
HN - Honduras 2
KZ - Kazakistan 2
NI - Nicaragua 2
NO - Norvegia 2
SN - Senegal 2
TG - Togo 2
XK - ???statistics.table.value.countryCode.XK??? 2
AD - Andorra 1
AM - Armenia 1
BB - Barbados 1
BG - Bulgaria 1
BH - Bahrain 1
BW - Botswana 1
BY - Bielorussia 1
Totale 13.585
Salva come PNG Salva come JPEG
Città #
Singapore 746
Dallas 633
Ashburn 534
San Jose 453
Dublin 434
Chandler 397
Ann Arbor 339
Parma 299
Santa Clara 289
Hong Kong 269
Beijing 232
Council Bluffs 209
Ho Chi Minh City 180
Dearborn 155
Jacksonville 151
New York 140
Boardman 139
Hanoi 139
Los Angeles 129
Johannesburg 124
Shanghai 100
Munich 93
Milan 92
Hefei 88
Nanjing 87
Lauterbourg 76
Princeton 68
Izmir 65
Chicago 63
Bremen 60
Helsinki 52
Bologna 48
Vienna 46
Buffalo 43
Abidjan 41
Nanchang 41
São Paulo 41
San Mateo 40
Shenyang 37
Wilmington 36
Modena 35
Moscow 34
The Dalles 34
Brussels 31
Haiphong 31
Hebei 28
Kunming 28
Columbus 27
Da Nang 27
Rome 26
Toronto 26
Jinan 25
Marseille 25
Seattle 25
Frankfurt am Main 24
Tianjin 24
Warsaw 24
Levanto 23
Seoul 23
Des Moines 22
Tokyo 22
Jakarta 21
London 21
Redmond 20
Turku 20
Stockholm 19
Denver 18
Nuremberg 17
Woodbridge 17
Guangzhou 16
Manchester 16
Orem 16
Phoenix 16
Chennai 15
Pune 15
Reggio Emilia 15
Amsterdam 14
Atlanta 14
Bari 14
Brescia 14
Florence 14
Houston 14
Norwalk 14
Boston 13
Changsha 13
Jiaxing 13
Montreal 13
Poplar 13
Rio de Janeiro 13
Dhaka 12
Naples 12
Neviano degli Arduini 12
Wayne 12
Brooklyn 11
Leawood 11
New Delhi 11
Verona 11
Baghdad 10
Biên Hòa 10
Fremont 10
Totale 8.332
Salva come PNG Salva come JPEG
Nome #
Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR 353
Targeting metabolic adaptive responses induced by glucose starvation inhibits cell proliferation and enhances cell death in osimertinib-resistant non-small cell lung cancer (NSCLC) cell lines 285
Novel activity of a synthetic decapeptide against Toxoplasma gondii Tachyzoites 273
Efficacy of the cdk4/6 dual inhibitor abemaciclib in egfr-mutated nsclc cell lines with different resistance mechanisms to osimertinib 254
PD-L1 overexpression induces STAT signaling and promotes the secretion of pro-angiogenic cytokines in non-small cell lung cancer (NSCLC) 254
Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models 249
CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells 222
Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines. 220
Pemetrexed enhances membrane PD-L1 expression and potentiates T cell-mediated cytotoxicity by anti-PD-L1 antibody therapy in non-small-cell lung cancer 215
Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells. 213
CDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma Cells 212
Cell size reduction induced by inhibition of the mTOR/S6K signaling pathway protects Jurkat cells from apoptosis 210
Targeting PI3K somatic mutations reduces invasion and EMT in squamous cell carcinoma of the lung 208
Dual inhibition of CDK4/6 and PI3K/AKT/mTOR signaling impairs energy metabolism in MPM cancer cells 206
Effect of inducible FHIT and p53 expression in the Calu-1 lung cancer cell line 200
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC 200
Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatments 197
Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance 196
Characterization of gefitinib uptake in NSCLC cell lines 194
Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines 192
A Photoactive Supramolecular Complex Targeting PD-L1 Reveals a Weak Correlation between Photoactivation Efficiency and Receptor Expression Levels in Non-Small-Cell Lung Cancer Tumor Models 188
Creatine as a compatible osmolyte in muscle cells exposed to hypertonic stress 188
Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism. 187
Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation 185
Anti-proliferative effect of letrozole and sorafenib in MCF-7/AROM-1 breast cancer cells 185
Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines 180
Anti-proliferative effect of combining Letrozole with Sorafenib in MCF-7/Arom-1 breast cancer cells 180
Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification 180
Antiproliferative and proapototic effects of a new combi-molecule on non small cell lung cancer cell lines 179
Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations. 176
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines 176
Dose-dependent effect of FHIT-inducible expression in Calu-1 lung cancer cell line 175
Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer 175
Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion 174
Anti-proliferative effects of copper(II) complexes with hydroxyquinoline-thiosemicarbazone ligands 174
Corrigendum: CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells (Frontiers in Oncology, (2022), 12, (942341), 10.3389/fonc.2022.942341) 174
Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines 168
CDK4/6 INHIBITORS AS A NEW THERAPEUTIC APPROACH IN MESOTHELIOMA MODELS 167
Effect of specific PI3K/mTOR inhibitors in squamous lung cancer cells carrying PI3K alterations 165
Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN 161
Cancer of Unknown Primary: novel therapeutic opportunities from patient-derived cell cultures and in vivo models 161
Meccanismo d’azione di UPR 1024: un nuovo farmaco con attività antiproliferativa in cellule di carcinoma polmonare umano 160
Effects of FGFR1 inhibition on survival, proliferation, and energy metabolism in Non Small Cell Lung Cancer (NSCLC) cell lines 160
Anti-proliferative and pro-apoptotic effects of Sorafenib in breast cancer cells in vitro. 159
Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines 152
Synergistic activity of letrozole and sorafenib on breast cancer cells 150
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones. (Cavazzoni and Bonelli co-first authors) 149
Physico-chemical characterization and biological evaluation of two fibroin materials 147
Reprogramming of Lipid Metabolism in Lung Cancer: An Overview with Focus on EGFR-Mutated Non-Small Cell Lung Cancer 145
Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells 141
Immunotherapeutic approaches in malignant pleural mesothelioma 138
Role of sphingolipid metabolism in osimertinib-resistance in EGFR-mutated NSCLC models 137
The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells 137
Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines 137
Targeting FGFR1 pathway in non small cell lung cancer both in vitro and in vivo 136
Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib 136
Changes in glucose uptake after erlotinib treatment in NSCLC cell lines: a predictive and prognostic value? 136
Correction to: Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer (Cancers, (2020), 12, 3, (666), 10.3390/cancers12030666) 132
Overcoming Palbociclib Resistance by Combined Treatment with PI3K/AKT/mTOR Inhibitors in Mesothelioma Cells 132
Synergistic activity of letrozole and sorafenib on MCF7/AROM-1 breast cancer cells 131
Multiple effects of CDK4/6 inhibition in cancer: From cell cycle arrest to immunomodulation 131
Effect of constitutive or inducible expression of the FHIT gene in a lung cancer cell line 128
Synergic activity of FGFR2 and MEK inhibitors in the treatment of FGFR2-amplified cancers of unknown primary 126
null 126
Modulazione della riespressione del gene FHIT in cellule di carcinoma polmonare 125
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones 123
Targeting oncogenic PI3K/Akt/mTOR pathway in squamous cell lung carcinoma 121
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines 113
Impairing energy metabolism in solid tumors through agents targeting oncogenic signaling pathways 113
Pure anti-tumor effect of zoledronic acid in naive bone-only metastatic and locally advanced breast cancer: proof from the "biological window therapy" 112
Functional characterization of gefitinib uptake in non-small cell lung cancer cell lines 106
Espressione Inducibile del gene FHIT in cellule di carcinoma polmonare 105
Synergic anti-proliferative effect of gefitinib and RAD001 in non small cell lung cancer cell lines 104
Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer 101
Effect of inducible FHIT and p53 expression on CALU-1 cell proliferation. 101
Effect of letrozole and sorafenib on cell proliferation and apoptosis of MCF-7/AROM-1 breast cancer cell line 100
Increased level of inducible HSP70 in cells exposed to electromagnetic fields. 100
Targeting FGFR1 pathway in squamous cell lung cancer 99
Intrinsic Resistance to Osimertinib in EGFR Mutated NSCLC Cell Lines Induced by Alteration in Cell-Cycle Regulators 94
Erlotinib potentiates Cetuximab-dependent call citotoxicity in EGFR wild type NSCLC cell lines 94
Studio dell’espressione del gene FHIT in cellule di carcinoma polmonare 90
New therapeutic strategies for malignant pleural mesothelioma 84
Effect of inducible Fhit and p53 expression in Calu-1 lung cancer cell line 82
Evaluation of gefitinib maintenance in an EGFR-mutant NSCL cell line with acquired resistance 82
Espressione inducibile di FHIT e p53 in cellule Calu-1 81
Effect of constitutive expression of the fragile histidine triad gene on non small cell lung cancer 74
Effects of sorafenib on energy metabolism in breast cancer cells: Role of AMPK-mTORC1 signaling 45
null 31
Correction to: The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells (Journal of Experimental & Clinical Cancer Research, (2018), 37, 1, (72), 10.1186/s13046-018-0741-3) 14
CDK Inhibition as a new Potential Target Approach in Pleural Mesothelioma Models 9
The simultaneous inhibition of PI3K and AURORA A/B pathways induced a synergistic anti-tumor effect in preclinical models of NSCLC cells carrying PI3KCA mutations 7
Totale 13.787
Salva come PNG Salva come JPEG
Categoria #
all - tutte 44.895
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 44.895
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022384 0 15 21 38 15 10 70 30 22 19 30 114
2022/20231.695 148 178 118 108 159 195 14 143 528 9 74 21
2023/2024804 38 51 28 43 54 157 67 68 33 45 89 131
2024/20252.454 87 111 171 180 249 259 177 124 285 201 208 402
2025/20265.558 428 483 799 538 721 278 596 172 713 389 264 177
2026/2027422 176 246 0 0 0 0 0 0 0 0 0 0
Totale 13.787